Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
- Author
- Stephan Stilgenbauer, Therese Aurran Schleinitz, Barbara Eichhorst, Fabian Lang, Fritz Offner (UGent) , Jean-Francois Rossi, Wilfried Schroyens, Eric Van den Neste, Loic Ysebaert, Ute von Wangenheim, Uta Ursula Kress, Petra Blum and Thorsten Zenz
- Organization
- Keywords
- CD37, SAFETY
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 250.44 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8647161
- MLA
- Stilgenbauer, Stephan, et al. “Phase 1 First-in-Human Trial of the Anti-CD37 Antibody BI 836826 in Relapsed/Refractory Chronic Lymphocytic Leukemia.” LEUKEMIA, vol. 33, no. 10, 2019, pp. 2531–35, doi:10.1038/s41375-019-0475-z.
- APA
- Stilgenbauer, S., Schleinitz, T. A., Eichhorst, B., Lang, F., Offner, F., Rossi, J.-F., … Zenz, T. (2019). Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. LEUKEMIA, 33(10), 2531–2535. https://doi.org/10.1038/s41375-019-0475-z
- Chicago author-date
- Stilgenbauer, Stephan, Therese Aurran Schleinitz, Barbara Eichhorst, Fabian Lang, Fritz Offner, Jean-Francois Rossi, Wilfried Schroyens, et al. 2019. “Phase 1 First-in-Human Trial of the Anti-CD37 Antibody BI 836826 in Relapsed/Refractory Chronic Lymphocytic Leukemia.” LEUKEMIA 33 (10): 2531–35. https://doi.org/10.1038/s41375-019-0475-z.
- Chicago author-date (all authors)
- Stilgenbauer, Stephan, Therese Aurran Schleinitz, Barbara Eichhorst, Fabian Lang, Fritz Offner, Jean-Francois Rossi, Wilfried Schroyens, Eric Van den Neste, Loic Ysebaert, Ute von Wangenheim, Uta Ursula Kress, Petra Blum, and Thorsten Zenz. 2019. “Phase 1 First-in-Human Trial of the Anti-CD37 Antibody BI 836826 in Relapsed/Refractory Chronic Lymphocytic Leukemia.” LEUKEMIA 33 (10): 2531–2535. doi:10.1038/s41375-019-0475-z.
- Vancouver
- 1.Stilgenbauer S, Schleinitz TA, Eichhorst B, Lang F, Offner F, Rossi J-F, et al. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. LEUKEMIA. 2019;33(10):2531–5.
- IEEE
- [1]S. Stilgenbauer et al., “Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia,” LEUKEMIA, vol. 33, no. 10, pp. 2531–2535, 2019.
@article{8647161, author = {{Stilgenbauer, Stephan and Schleinitz, Therese Aurran and Eichhorst, Barbara and Lang, Fabian and Offner, Fritz and Rossi, Jean-Francois and Schroyens, Wilfried and Van den Neste, Eric and Ysebaert, Loic and von Wangenheim, Ute and Kress, Uta Ursula and Blum, Petra and Zenz, Thorsten}}, issn = {{0887-6924}}, journal = {{LEUKEMIA}}, keywords = {{CD37,SAFETY}}, language = {{eng}}, number = {{10}}, pages = {{2531--2535}}, title = {{Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia}}, url = {{http://doi.org/10.1038/s41375-019-0475-z}}, volume = {{33}}, year = {{2019}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: